In canine mammary carcinomas, loss of HER2 expression has been associated with a poor prognosis in combination with ER-negative status and positivity of basal cell markers (P-cadherin, p63, cytokeratin 5) (137). The gene discussed is ERBB2; the disease is breast carcinoma.